A Clinical Study of Early Chemotherapy in High Risk Hydatidiform Mole Patients

Song, H Y; Kim, J H; Park, D C; Yoo, Y O; Bae, S N; Kim, D H; Kim, S J; Namkoong, S E

Abstract

1616 hydatidiform mole (HM) patients have been treated in Korean Research Institude of Trophoblastic disease for the past twenty four years. These patients were divided into two groups, high risk and low risk group in accordance with the scoring system of Catholic University Medical colleage consisted of several factors such as age, gravity, hCG, mole type and uterine size. After evacuating mole, the overall remission rate was 76% and meanwhile, remission rate of high risk group was 69.2%. 31 out of 121 patients of high risk group were treated with early chemotherapy. In comparison with untreated group, data explained that the treated group with early chemotherapy needed less number of chemotherapy until complete remission (5.4+/-5.6 weeks versus 8.3+/-6.4 weeks p=0.0155). Further explained that the duration of chemotherapy for the treated group was shorter than that of the untreated group (16+/-23.93 weeks, versus 21.00+/-18.14 weeks p=0.335). Also, the statistics showed remarkable difference in the morbidity of disease (treated patient group with early chemotherapy 23.3+/-21.2 weeks versus untreated patient group 35.8+/-37.6, p=0.0346). In conclusion, early chemotherapy can reduce the duration of morbidity and numbers of chemotherapy.